World's Best Scientists 2026 revealed!
Drug Resistance Updates
H-index 49

Drug Resistance Updates

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Microbiology 184 25 21 11
Medicine 1491 32 30 17

Additional Metrics

Number of Best Scientists*: 139
Documents by Best Scientists*: 139
Top 100 Ranked Scientists*: 4
SCIMAGO H-index: 139
SCIMAGO SJR: 5.282
Impact Factor: 21.7

Overview

Top Research Topics at Drug Resistance Updates?

Drug resistance, Cancer research, Pharmacology, Cancer and Cancer cell are the subjects of interest in the journal. It holds forums on Drug resistance that merges themes from other disciplines such as Antibiotic resistance, Chemotherapy and Drug. The presented Cancer research research focuses mostly on Immunology and, on occasion, topics in Disease.

Clinical trial, Transporter, Efflux, Kinase and In vivo are some topics wherein Pharmacology research discussed in Drug Resistance Updates have an impact. The journal explores issues in Cancer which can be linked to other research areas like Oncology and Bioinformatics. Drug Resistance Updates focuses on Cancer cell but the discussions also offer insight into other areas such as Apoptosis, Programmed cell death and Cell biology.

Most of the Cell biology studies addressed also intersect with Cell growth. Topics in Microbiology were tackled in line with various other fields like Genetics and Bacteria. The studies tackled, which mainly focus on Multiple drug resistance, apply to ATP-binding cassette transporter as well.

  • Drug resistance (32.57%)
  • Cancer research (26.06%)
  • Pharmacology (23.62%)

What are the most cited papers published in the journal?

  • ROS stress in cancer cells and therapeutic implications. (1482 citations)
  • Aminoglycoside Modifying Enzymes (692 citations)
  • Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations (651 citations)

Research areas of the most cited articles at Drug Resistance Updates:

The journal papers facilitate discussions on Drug resistance, Pharmacology, Microbiology, Cell biology and Cancer cell. While work presented in the most cited articles provide substantial information on Drug resistance, it also covers topics in Efflux, Immunology and Drug. While the published articles focused on Cancer cell, they were also able to explore topics like Apoptosis and Mitochondrion.

What topics the last edition of the journal is best known for?

  • Gene
  • Cancer
  • Enzyme

The previous edition focused in particular on these issues:

Drug Resistance Updates mostly deals with topics like Cancer research, Drug resistance, Drug, Multiple drug resistance and Cancer. Topics in Cancer research explored in Drug Resistance Updates were investigated in conjunction with research in Druggability, Autophagy, DNA damage and DNA repair. Drug resistance research presented in Drug Resistance Updates encompasses a variety of subjects, including Precision medicine and Docetaxel.

The studies in Drug featured incorporate elements of Cancer cell, Biomarker (cell), Androgen deprivation therapy, Anti-Androgen and Radiation therapy. Some problems in Cancer cell that were presented in it overlapped with concepts under Chemosensitivity assay, Pinocytosis, Cell biology, Computational biology and Endosome. It explores research in Multiple drug resistance alongside concepts in Efflux and other areas of study in ATP-binding cassette transporter.

The most cited articles from the last journal are:

  • Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance (16 citations)
  • Taxanes in cancer treatment: Activity, chemoresistance and its overcoming (14 citations)
  • Therapeutic strategies to overcome taxane resistance in cancer. (7 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Drug Resistance Updates (based on the number of publications) are:

  • Yehuda G. Assaraf (43 papers) published 8 papers at the last edition, 5 less than at the previous edition,
  • Zhe-Sheng Chen (13 papers) published 5 papers at the last edition, 1 more than at the previous edition,
  • Henk J. Broxterman (12 papers) absent at the last edition,
  • Nafsika H. Georgopapadakou (11 papers) absent at the last edition,
  • Elisabeth G.E. de Vries (7 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Drug Resistance Updates (based on the number of publications) are:

  • Technion – Israel Institute of Technology (53 papers) published 8 papers at the last edition, 6 less than at the previous edition,
  • University of Texas MD Anderson Cancer Center (17 papers) absent at the last edition,
  • National Institutes of Health (17 papers) absent at the last edition,
  • Harvard University (15 papers) absent at the last edition,
  • VU University Medical Center (14 papers) absent at the last edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 0.00% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 57.14% were posted by at least one author from the top 10 institutions publishing in the journal. Another 14.29% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 7.14% of all publications and 21.43% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Top Publications

  • Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance

    Nuray Erin;Jelena Grahovac;Anamaria Brozovic;Thomas Efferth

    (2020)
    345 Citations
  • The role of alternative splicing in cancer: From oncogenesis to drug resistance.

    Rocco Sciarrillo;Anna Wojtuszkiewicz;Yehuda G. Assaraf;Gerrit Jansen

    (2020)
    178 Citations
  • Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.

    Elisabeth Pérez-Ruiz;Ignacio Melero;Joanna Kopecka;Ana Bela Sarmento-Ribeiro

    (2020)
    133 Citations
  • Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.

    Anna Artese;Valentina Svicher;Giosuè Costa;Romina Salpini

    (2020)
    99 Citations
  • Antibiotic failure: Beyond antimicrobial resistance

    (2023)
    75 Citations
  • Repurposing old drugs to fight multidrug resistant cancers

    Jelena Dinić;Thomas Efferth;Alfonso T. García-Sosa;Jelena Grahovac

    (2020)
    71 Citations
  • The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies

    (2022)
    70 Citations
  • Precision medicine: Ray of hope in overcoming cancer multidrug resistance.

    (2022)
    69 Citations
  • Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability.

    (2022)
    69 Citations
  • Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.

    M. Chiappa;F. Guffanti;F. Bertoni;I. Colombo

    (2021)
    64 Citations

Related Online Degrees & Career Pathways

For those interested in healthcare but seeking alternatives to becoming a physician, there are numerous related online degree programs and career options. One promising field is medical billing and coding. Understanding the medical billing and coding outlook can help prospective students evaluate job stability and growth opportunities in this crucial administrative sector.

Health Information Management (HIM) is another rewarding pathway. Many universities now offer health information management online programs that equip students with skills to handle electronic health records and patient data securely, roles that are increasingly vital in modern healthcare systems.

Nutrition also plays a key role in patient care and wellness. For those passionate about promoting healthy lifestyles, exploring online degrees in nutrition can open doors to careers such as dietitians or nutrition consultants who impact community health through diet and lifestyle changes.

Additionally, technical roles like sonography offer hands-on patient interaction without the lengthy commitment of medical school. Investigating online ultrasound tech programs provides insight into training pathways that lead to diagnostic imaging careers, a field in high demand with solid growth prospects.

Best Scientists Contributing to This Journal

Recently Published Articles